BREAKING
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 10 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 12 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 12 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 3 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 4 days ago Synopsys Q1 2026 Earnings Results 4 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 10 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 12 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 12 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 3 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 4 days ago Synopsys Q1 2026 Earnings Results 4 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago
ADVERTISEMENT

Earnings: Array BioPharma delivers strong Q2 results, investors cheer

Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of $40 million of milestone revenue from Loxo Oncology.  The top line came in well above street projection of $49.02 million. Net loss was cut down to 5 cents per share from 17 cents per share […]

February 5, 2019 1 min read
News
“

Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of $40 million of milestone revenue from Loxo Oncology.  The top line came in well above street projection of $49.02 million. Net loss was cut down to 5 cents per share from 17 cents per share […]

· February 5, 2019

Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of $40 million of milestone revenue from Loxo Oncology.  The top line came in well above street projection of $49.02 million.

Net loss was cut down to 5 cents per share from 17 cents per share last year. Analysts were expecting a loss of 16 cents per share.

ARRY shares popped 3.2% during pre-market trading post the earnings announcement. The stock has gained 35% in the trailing 12 months.

CEO Ron Squarer said, “We continue to be pleased with demand following the US launch of BRAFTOVI + MEKTOVI for patients with BRAF-mutant metastatic melanoma, which delivered $22.7 million in net product sales during the second commercial quarter.”

ADVERTISEMENT

BRAFTOVI + MEKTOVI net product sales soared 62% in the US compared to the prior sequential quarter. The combination has also been launched in Germany, Austria, the Netherlands, and the United Kingdom

The Boulder, Colorado-based biotechnology firm has partnered with Bristol-Myers Squibb (BMY), Merck (MRK) and Pfizer (PFE) to study numerous cancer drug combinations.

 

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

ADVERTISEMENT

Related Articles